Merz Therapeutics’ Post

The rise of personalized medicine is reshaping the pharmaceutical landscape, with 𝟲𝟴% of surveyed physicians already integrating it into their practice. Our research indicates that the market will grow at a CAGR of 𝟭𝟭.𝟰%, driven primarily by oncology, cardiology, and neurology. Despite strong adoption, concerns about costs persist, highlighting the need for affordable solutions. North America and Europe lead the market, while Asia-Pacific shows significant investment in research. As AI and genetic testing gain traction, personalized medicine offers promising growth. Explore our latest insights at GRG Health. https://lnkd.in/gV_DwF5y #PersonalizedMedicine #PharmaTrends #HealthcareInnovation #Genomics #Oncology #Cardiology #AIinHealthcare #MarketResearch #GeneticTesting #GRGHealth Manan Sethi

Amylyx Pharmaceuticals announced today that RELYVRIO did not meet the prespecified primary or secondary endpoints from the Phase III clinical trial for amyotrophic lateral sclerosis (ALS).    The topline results from the Phase III trial found that after studying 664 ALS patients, Amylyx's drug failed to show statistically significant outcomes in comparison to placebo. At this time, RELYVRIO is still available to those living with ALS.    #Amylyx #RELYVRIO #ALS #Neurology   Read more: https://lnkd.in/d-HPn6v6

We understand wrapping your head around some of the terminology for Pancreatic Cancer can be intimidating. Our mother was a registered nurse in the Health Sciences, working in Neurosurgery and Obstetrics for almost twenty-five years. When she was undergoing treatment, she always told us the sheer amount of information coming at you is overwhelming, even as a medical professional. So we’ve decided to create a reference glossary on the page, which will help you quickly link to quick explanations of medical jargon and click through to credible resources to learn more. This is still in the early stages of development, and we’re still extracting common terms from articles. The more knowledgeable you are about this cancer, the more informed you can be about a decision you can make regarding your care. Look for video content coming your way soon! https://lnkd.in/d-TKansD #pancreaticcancer #CancerAwareness #pancreaticcancerawareness

📄 July #eanResearchHighlights present key findings in neurology: ➡️The N-MOmentum trial's open-label period shows sustained benefits of inebilizumab, a B-cell depleting anti-CD19 antibody, for NMOSD, including lower attack rates and fewer hospitalisations. ➡️ A phase 2 trial reveals brigatinib, a tyrosine kinase inhibitor, as a potential treatment for NF2-related schwannomatosis, with reduced tumour growth and improved symptoms. 🔗 Read more here: https://ow.ly/b5hE50SIsx9

🌍 Today is #WorldPsoriasisDay – a reminder of the millions who live with this chronic autoimmune condition and the need for continued advancements in treatment options. At InnoSer, we’re proud to contribute to this mission by offering preclinical research services essential for the study and development of novel psoriasis therapies. Our IL-23 induced research model has become an invaluable tool in advancing our understanding of psoriasis, providing insights into the mechanisms that drive inflammation and skin pathology. Read more about how you can utilize this model in your research here: https://lnkd.in/eT3QZmp9. #WorldPsoriasisDay #PsoriasisResearch #PreclinicalResearch #CRO #InnoSer #LifeSciences #IL23Model #AutoimmuneResearch

Changing the paradigm of clinical trials with #iBox Really excited to present our new study just released in clinical journal of the American Society of Nephrology 👉 Real World evidence using qualified high-quality reference set emulated #RCT shows long-term clinical #benefit for patients converted to #Belatacept  💊 We are providing evidence on the benefit and safety of this #alternative of CNI Standard of Care immunosuppression in Kidney transplant patients:  -> Adoption and extension of context of use  -> Fast tracking drug approval -> Lien 👉 https://bit.ly/CJASN0411 Special Thanks to Our Partners #PITOR #iBox #trialBox ! Kudos to the amazing partnership with Bristol Myers Squibb Radu Vadanici Predict4Health OrganX Foundation MSDAVENIR Bruno Bonnell Lise ALTER Antoine Tesniere Amy Abernethy Inserm AP-HP, Assistance Publique - Hôpitaux de Paris ESOT - European Society for Organ Transplantation American Society of Transplant Surgeons Université Paris Cité SFT - Société Francophone de Transplantation Agence du Numérique en Santé AGENCE DE LA BIOMEDECINE ANR (Agence nationale de la recherche)

Contribute to Patient Care: Submit Your Hematology Research Url: https://lnkd.in/gDgE_iAF #CancerTreatment #Hematopoiesis #TumorBiology #PrecisionOncology #HematologicDiseases #HematologyOncology #HematologyJournal #OncologyJournal

🧠✨ Unveiling innovation in #PediatricGlioblastomaTherapy: Silica-coated mixed polymeric micelles take the spotlight! 🌈🔬 Glioblastoma (GBM) is the malignant brain tumor of the primary central nervous system (CNS) arising from the glial cells having an incidence ranging from 5 to 8 persons per 100,000 individuals. The median survival rate is around 12 to 18 months with the current therapies. The drug which has been selected for this research was pitavastatin (PTV) which has a good encapsulation ability with PMs. The work aims at investigating the nanoencapsulation of PTV within cRGDfV-decorated mixed Pluronic® _F127 (F127) and Tetronic® _1307 (T1307) PMs that were further coated with silica gel for more physical stability and better control of kinetics release for brain targeting. 🎯🔍 Watch our video @ https://lnkd.in/gbDnTkST and moving closer to a future where pediatric patients can face their battles with more effective and targeted treatments.🧠👶 #PediatricCancerWarriors #GlioblastomaResearch #InnovationInMedicine #HopeInScience #GlioblastomaMultiforme #GlioblastomaMultiformeTreatment #GlioblastomaMultiformeSymptoms #PediatricGlioblastomaTreatment #PediatricGlioblastomaSymptoms #CellTalk #LifeScinces #Journal #HealthJournal #JournalClub #GeneralCellTalk #ResearchArticle #ClinicalTrails

XO Cath is 40% More Pushable Than Leading Competitive Small Lumen Microcatheter The proprietary laser-cut hypotube design creates a great balance between flexibility and pushability to enable physicians to navigate through challenging vasculature to deploy embolic agents and therapeutics. The XO Cath (2.0F / 0.021” ID) is a low-profile microcatheter with minimal taper allowing for broad embolic agent compatibility without sacrificing performance when accessing small, tortuous vasculature. #XOCath #interventionalradiology #embolization #interventionaloncology

We are looking forward to #SNIS2024, where preclinical middle meningeal artery (MMA) embolization study results will be presented. Note the visibility of the #IMPASSembolic in the image below. #neurointerventional #embolization #MMAembolization #subduralhematoma #interventionaloncology #interventionalradiology